Observation on the efficacy of clopidogrel and agaptenin in patients with cerebral infarction beyond the thrombolysis time window
替罗非班和阿加曲班针剂治疗超溶栓时间窗脑梗死患者疗效观察

摘要

目的 观察替罗非班和阿加曲班针剂治疗超溶栓时间窗脑梗死患者的疗效。方法 采用随机单双数入组对照试验法，选取2024年1月-2024年12月间52例超过溶栓时间窗的脑梗死患者，单数序列入组的26例为研究组，接受替罗非班治疗；双数序列入组的26例为对照组，接受阿加曲班治疗，两组基础治疗相同。比较两组患者临床疗效和安全性指标。结果 研究组治疗后NIHSS评分较对照组下降更显著（P<0.05），ADL生活质量评分提升更明显（P<0.05），脑梗死复发率为7.7%（2/26）低于对照组的23.1%（6/26）；两组颅内出血率、全身性出血事件发生率及其他不良反应发生率差异无统计学意义（P>0.05）。研究组治疗后的炎症因子指数优于对照组（P>0.05）。结论 在超溶栓时间窗脑梗死患者治疗中，替罗非班在改善神经功能、提升生活质量及降低复发率方面优于阿加曲班，安全性相当。

Abstract

Objective To evaluate the efficacy of ticlopidine and aganocine in treating patients with cerebral infarction who have exceeded the thrombolysis time window.
Methods A randomized single-double number group control trial was conducted, selecting 52 patients with cerebral infarction who had exceeded the thrombolysis time window between January and December 2024. The 26 patients in the odd-numbered sequence were assigned to the study group and received ticlopidine treatment; the 26 patients in the even-numbered sequence were assigned to the control group and received aganocine treatment, with both groups receiving the same basic treatment. The clinical efficacy and safety indicators of the two groups were compared.
Results After treatment, the NIHSS score in the study group decreased more significantly (P<0.05) compared to the control group, and the ADL quality of life score improved more markedly (P<0.05). The recurrence rate of cerebral infarction was 7.7% (2/26) in the study group, which was lower than the 23.1% (6/26) in the control group. There was no statistically significant difference in the incidence of intracranial hemorrhage, systemic bleeding events, and other adverse reactions between the two groups (P>0.05). The inflammatory factor index in the study group after treatment was better than that in the control group (P>0.05).
Conclusion   In the treatment of patients with cerebral infarction who have exceeded the thrombolysis time window, ticlopidine is superior to aganocine in improving neurological function, enhancing quality of life, and reducing recurrence rates, with comparable safety.